DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* ERYTECH PHARMA *


 

2004 - Rhône-Alpes
Lyon
www.erytech.com

 

Delivery, Drugs
Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery, Vaccin'Ery, Graspa
Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients
Clients: Prescribers
contact@erytech.com

Age: 12 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Beyen (Gil) [M.Sc. Bioengineering (Belgium), MBA, ex-TiGenix, Arthur D. Little] and Goineau (Pierre-Olivier) [co-founder, born 1967, MBA IAE Lyon, ex-KPMG]
Oper.Dir.:
Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
Pharm.Dir.: Bailly (David) [Pharm.Dr, Chem.Eng. (Montréal), ex-Skyepharma, Aguettant]
Fin.Dir.-CFO:
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys, Idinvest

Turnover (M€) : n.a.
Total funding (M€) : 22
Last funding (M€) : 12.0
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2013 .03 Registration : FDA IND allowance for beginning Phase I with Grespa (USA traded as Eryasp) MKTG [8 years]
2012 .08 Nomination : Gil Beyen, new CEO, Pierre-Olivier Goineau, co-founder, moved to delegate general manager ORGN [7 years]
2012 .07 Registration : orphan Drug designation by EMA for investigational product Enhoxy for sickle cell disease MKTG [7 years]
2012 .06 Financing (no interest loan) : 6.95 M€, by OSEO, to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy), within consortium including Exonhit, InGen BioSciences, AP-HP, Inserm and Paris-Diderot University DEBT [7 years]
2011 .05 Partnering distribution agreement with Teva on encapsulated drugs in red cells MKTG [6 years]
2010 .10 Partnering R&D agreement with Genzyme on novel therapeutic enzyme formulation R&D [5 years]
2010 .01 Registration : orphan Drug designation by FDA for GRASPA MKTG [5 years]
2009 .01 Partnering R&D agreement with American Red Cross to produce Graspa for clinical trials in USA R&D [4 years]
2008 .10 Clinical trial (phase II) for new vaccine concept against cancer, based on red blood cells, Vaccin'ERY (completed, positive) CLIN [3 years]
2008 .05 Clinical trial (phase II) for Graspa (orphan drug) in leukemia (completed) CLIN [3 years]
2006 .11 1st round-financing : 12.0 M€, by AXA P.E., Auriga Partners, AGF P.E., Capdecisif RFINA [2 years]
2006 .06 Registration : orphan Drug designation by EMEA for GRASPA MKTG [1 year]
2005 .11 Clinical trial (phase II) for lead compound in leukemia (beginning) CLIN [1 year]
2005 .10 Seed financing : 0.75 M€, by Amorçage Rhône Alpes (+ 0.45 M€ from contest by French Ministry of R&D) SFIN [0 year]
2004 .11 Company founded by Yann Godfrin and Pierre-Olivier Goineau ORGF [0 year]

Actualisation / Updating: 19-Apr-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende